IMPACT-ADT Trial
Phase 2
60
about 2.3 years
30–79
Male only
1 site in CA
What this study is about
This trial is testing whether time-restricted eating, GLP1 receptor agonists (semaglutide and tirzepatide), or a heart healthy diet improves cardiovascular health in prostate cancer patients receiving androgen deprivation therapy. Prostate cancer patients undergoing hormonal therapy are at increased risk of cardiovascular disease due to metabolic changes. It compares these interventions to see if they can improve cardiovascular and metabolic health.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Electronic Health Record Review
- 2.Internet-Based Intervention
- 3.Medical Device Usage and Evaluation
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
semaglutide (GLP-1 agonist; stimulates insulin release), tirzepatide
oral (Oral Tablet), injection (Injection)
Secondary: Quality of life - International Prognostic Scoring System, Quality of life - Merrick rectal function, Quality of life - Patient Reported Outcomes Measurement Information System 29, Quality of life - Sexual Health Inventory for Men
diagnostic, angiography, imaging, radiation